DOCSLIB.ORG

The Radiopharmacy a Technologist’S Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Radiopharmacy a Technologist’S Guide Eur e opea icin n Association of Nuclear Med The Radiopharmacy A Technologist’s Guide Produced with the kind Support of Contributors James R Ballinger, PhD Helen Ryder Chief Radiopharmaceutical Scientist Clinical Specialist Radiographer Guy’s and St Thomas’ NHS Foundation Trust Dept. of Diagnostic Imaging London, United Kingdom St. James’s Hospital Dublin, Ireland Clemens Decristoforo, PhD (*) Chair of the EANM Radiopharmacy Committee Tanja Gmeiner Stopar, PhD Clinical Department of Nuclear Medicine Member of the Education Board, Medical University Innsbruck EANM Radiopharmacy Committee Innsbruck, Austria Radiopharmacy, Head University Medical Centre Ljubljana Brit Farstad Department for Nuclear Medicine Member of the EANM Radiopharamcy Committee Ljubljana, Slovenia M.Pharm/Radiopharmacist Department Head, Isotope Laboratories Wim van den Broek Institute for Energy Technology Chair of the EANM Technologist Committee Kjeller, Norway Chief Technologist Dept of Nuclear Medicine Brendan McCoubrey University Medicine Centre Radiation Safety Officer Nijmegen, The Netherlands Dept. of Diagnostic Imaging St. James’s Hospital Editors Dublin, Ireland Suzanne Dennan Geraldine O’Reilly, PhD Vice-Chair of the EANM Technologist Committee Acting Radiographic Services Manager Radiation Protection Advisor Dept. of Diagnostic Imaging Dept. of Medical Physics and BioEngineering St. James’s Hospital St. James’s Hospital Dublin, Ireland Dublin, Ireland Clemens Decristoforo, PhD * This booklet was sponsored by an educational grant from Lantheus Medical Imaging . The views expressed are those of the authors and not necessarily of Lantheus Medical Imaging. 2 Contents Foreword Wim van den Broek. 4 Introduction Clemens Decristoforo. 5 Chapter 1 - Radiopharmacy Technology Brit Farstad. 6 Chapter 2 - Radiopharmacy Design James Ballinger. .12 Chapter 3 - Radiopharmacy: Preparing & Dispensing Radiopharmaceuticals EANM Geraldine O’Reilly. .16 Chapter 4 - Radiopharmacy: Kits & Techniques Helen Ryder. 22 Chapter 5 – Radiopharmacy: Blood Labelling Tanja Gmeiner Stopar. .33 Chapter 6 - Radiopharmacy: Record Keeping & Administration Brendan McCoubrey. 41 References. .49 Imprint. .51 3 Foreword Wim van den Broek Since it was formed, the EANM Technologist should be provided for all staff working in ra- Committee has been devoted to the improve- diopharmacy departments in the aspects of ment of nuclear medicine technologists’ quality assurance in which they are involved. (NMTs’) professional skills. Publications that will This includes: preparation, release, quality con- assist in the setting of high standards for NMT’s trol and analytical techniques, cleaning, trans- work have been developed and since 2004 portation, calibration of equipment (especially a series of brochures, “Technologists Guides”, for the measurement of radioactivity), working have been published yearly. This booklet practices in the radiopharmacy, preparation of about radiopharmacy is already the fifth vol- the individual doses, documentation, hygiene, ume. The new and stricter regulations in the pharmaceutical microbiology, and microbio- field of preparation of radiopharmaceuticals logical monitoring. Often a Nuclear Medicine changed the daily practice in the radiophar- Technologist is the person who is involved macy in the last 5 years. in the preparation and quality control of the radiopharmaceuticals. Nuclear medicine is a multidisciplinary special- ty in which medicine, physics and pharmacy I am grateful for the effort and hard work of all are involved. The Radiopharmacy is an integral the contributors, who are the key to the con- part of a nuclear medicine department and its tents and educational value of this booklet. prime responsibility is the preparation of high The most essential and relevant aspects of ra- quality radiopharmaceuticals, the base for a diopharmacy in daily practice are emphasised high quality nuclear medicine examination. here. This booklet is prepared in cooperation The majority of these radiopharmaceuticals with the Radiopharmacy Committee of the is mainly used for diagnostic imaging, which EANM. This Committee is very active and criti- is the main activity of nuclear medicine. Ra- cal in the field of regulations and guidelines for diopharmaceuticals are medical products the production of radiopharmaceuticals and defined in the European directive 2004/27/ constantly proposes practical solutions. Many EC amending the directive 2001/83/EC. As in thanks to Suzanne Dennan who coordinated other disciplines the complex changes driven this project. by European legislation had their impact on everyday practice in the preparation of radio- With this new booklet, the EANM Technolo- pharmaceuticals. gist Committee offers to the NMT community again a useful and comprehensive tool that Only trained people should be responsible for may contribute to the advancement of their and participate in the preparation and qual- daily work. ity control of radiopharmaceuticals. Training 4 Introduction Clemens Decristoforo, PhD I want to congratulate the Technologists Com- The Technologists Committee of the EANM mittee of the EANM for this excellent Tech- has been very active in promoting profes- nologists Guide on the Radiopharmacy. Issues sional skills of technologists and to support of quality assurance especially in the field of high quality standards in daily practice. The pharmaceutical preparations are becoming series of “Technologists Guide” booklets by the increasingly important. The Radiopharmacy Eductional Sub-Committee has been a valu- Committee of the EANM therefore recently able part of these initiatives. The current issue has issued general guidelines for “Current of this series intends to provide guidance for Good Radiopharmacy Practice” describing a “good radiopharmacy practice,” to describe the quality standards in the preparation of quality standards and to bring radiopharmacy conventional and PET radiopharmaceuticals practice to equal standards throughout Eu- (http://www.eanm.org/scientific_info/guide- rope. EANM lines/gl_radioph_cgrpp.php). These serve as a general reference standard for radiophar- This booklet contains chapters of all relevant maceutical preparation as radiopharmacy topics of daily radiopharmacy practice of tech- practice still shows a great variability all over nologists such as radiopharmacy design, prep- Europe. aration and dispensing as well as documenta- tion written by European experts in the field, Technologists in many countries are the both radiopharmacists and technologists. backbone for radiopharmacy services within nuclear medicine departments. This is espe- I am very confident that this booklet will not cially true for the preparation and handling only provide valuable information and quick of conventional radiopharmaceuticals includ- reference for problems arising in daily prac- ing eluting radionuclide generators, prepara- tice, but also will help to continuously improve tion of 99mTc-radiopharmaceuticals from kits, quality standards of radiopharmacy practices dispensing and cell labelling. Therefore the in nuclear medicine. current issue of the Technologists Guides is dedicated to radiopharmacy practice. 5 Chapter 1 – Radiopharmacy Technology Brit Farstad Radiopharmacy A radiopharmaceutical can be as simple as a Radiopharmacy encompasses studies related radioactive element such as 133Xe, a simple salt to the pharmaceutical, chemical, physical, such as 131I-NaI, or a labelled compound such biochemical, and biological aspects of ra- as 131I-iodinated proteins and 99mTc-labeled diopharmaceuticals. Radiopharmacy com- compounds. prises a rational understanding of the design, preparation and quality control of radiophar- Usually, radiopharmaceuticals contain at least maceuticals, the relationship between the two major components: physiochemical and biological properties of radiopharmaceuticals and their clinical appli- • A radionuclide that provides the desired cation, as well as radiopharmaceuticals chem- radiation characteristics. istry and issues related to the management, selection, storage, dispensing, and proper use • A chemical compound with structural or of radiopharmaceuticals. chemical properties that determine the in vivo distribution and physiological behav- Characteristics of radiopharmaceuticals iour of the radiopharmaceutical. A radiopharmaceutical is a pharmaceutical that, when ready for use, incorporates one Radiopharmaceuticals should have several or more radionuclides (radioactive isotopes). specific characteristics that are a combination Radiopharmaceuticals are used for diagnosis of the properties of the radionuclide used as or therapeutic treatment of human diseases; the label and of the final radiopharmaceutical hence nearly 95% of radiopharmaceuticals are molecule itself. used for diagnostic purposes, while the rest is used for therapy. Decay of radionuclides Radionuclides are unstable nuclei that are sta- Radiopharmaceuticals usually have no phar- bilised upon radioactive decay. Approximately macologic effects, as they are used in tracer 3000 nuclides have been discovered so far; quantities. There is no dose-response relation- most of these are unstable, but only about 30 ship in this case, which thus differs significantly of these are routinely used in nuclear medicine. from conventional drugs. Most of these are artificial radionuclides, which may be produced by irradiation in nuclear re- Radiation is an inherent characteristic of all actors, cyclotrons, or large linear accelerators. radiopharmaceuticals, and
Load more

Recommended publications
  • Design of Neutron and Gamma Ray Diagnostics for the Start-Up Phase of the DTT Tokamak
    46th EPS Conference on Plasma Physics P5.1105 Design of neutron and gamma ray diagnostics for the start-up phase of the DTT tokamak M. Angelone 1, D. Rigamonti 2, M Tardocchi 2, F. Causa 2, S. Fiore 1, L. C. Giacomelli 2, G. Gorini 3,2 , F. Moro 1, M. Nocente 3,2 , M. Osipenko 4, M. Pillon 1, , M. Ripani 4, R. Villari 1 1ENEA, Centro Ricerche Frascati, Frascati, Italy 2Istituto per la Scienza e Tecnologia dei Plasmi, CNR, Milan, Italy 3Dipart. di Fisica “G. Occhialini”, Università degli Studi di Milano-Bicocca, Milano, Italy 4Istituto Nazionale di Fisica Nucleare, Genova, Italy e-mail : [email protected] Abstract The Divertor Tokamak Test (DTT) facility, which is under design for construction in Frascati (Italy), will produce neutron yield up to 1.3*10 17 n/s at full power (H-mode scenario). This calls for an accurate design and selection of the 2.5 MeV neutron diagnostic systems and detectors which can give the comprehensive exploitation of the high neutron fluxes. Measurements of 14 MeV neutrons (which are about 1% of the total neutron yield) coming from the triton burn-up will also be performed. DTT will reach its best performances after a preliminary phase , needed to assess and improve the machine parameters. Here we present the neutron and gamma-ray diagnostics systems which are under design for the initial start-up phase of DTT. The design work benefits from the experience gathered by the community on high power tokamak such as JET. These systems, also called day-1 diagnostics, are: i) Neutron flux monitors which measure the 2.5 and 14 MeV neutron yield s, ii) Neutron/Gamma camera for the reconstruction of the neutron and gamma ray emission profile of the plasma , iii) Hard x-ray monitors for measurements of the bremsstrahlung radiation produced by runway electrons in the 1-40 MeV energy range 1.0 Introduction The Divertor Tokamak Test (DTT) facility, which is under design for construction in Frascati (Italy), will produce neutron yield up to 1.3*10 17 n/s at full power (H-mode scenario).
    [Show full text]
  • Radioisotopes and Radiopharmaceuticals
    RADIOISOTOPES AND RADIOPHARMACEUTICALS Radioisotopes are the unstable form of an element that emits radiation to become a more stable form — they have certain special attributes. These make radioisotopes useful in areas such as medicine, where they are used to develop radiopharmaceuticals, as well as many other industrial applications. THE PRODUCTION OF TECHNETIUM-99m RADIOPHARMACEUTICALS: ONE POSSIBLE ROUTE IRRADIATED U-235 99 TARGETS MO PROCESSING FACILITY HOSPITAL RADIOPHARMACY (MIXING WITH BIOLOGICAL MOLECULES THAT BIND AT DIFFERENT LOCATIONS IN THE 99mTC IS IDEAL FOR DIAGNOSTICS BECAUSE OF BODY, SUPPORTING A WIDE ITS SHORT HALF-LIFE (6 HOURS) AND IDEAL GAMMA EMISSION RANGE OF MEDICAL NUCLEAR APPLICATIONS) REACTOR: 6 HOURS MAKES DISTRIBUTION DIFFICULT 99MO BULK LIQUID TARGET ITS PARENT NUCLIDE, MOLYBDENUM-99, IS PRODUCED; ITS HALF-LIFE (66 HOURS) MAKES 99 99m IRRADIATION IT SUITABLE FOR TRANSPORT MO/ TC GENERATORS 99MO/99mTC GENERATORS ARE PRODUCED AND DISTRIBUTED AROUND THE GLOBE 99MO/99TC GENERATOR MANUFACTURER Radioisotopes can occur naturally or be produced artificially, mainly in research reactors and accelerators. They are used in various fields, including nuclear medicine, where radiopharmaceuticals play a major role. Radiopharmaceuticals are substances that contain a radioisotope, and have properties that make them effective markers in medical diagnostic or therapeutic procedures. The chemical presence of radiopharmaceuticals can relay detailed information to medical professionals that can help in diagnoses and treatments. Eighty percent of all diagnostic medical scans worldwide use 99mTc, and its availability, at present, is dependent on the production of 99Mo in research reactors. Globally, the number of medical procedures involving the use of radioisotopes is growing, with an increasing emphasis on radionuclide therapy using radiopharmaceuticals for the treatment of cancer..
    [Show full text]
  • OPERATIONAL GUIDANCE on HOSPITAL RADIOPHARMACY: a SAFE and EFFECTIVE APPROACH the Following States Are Members of the International Atomic Energy Agency
    OPERATIONAL GUIDANCE ON HOSPITAL RADIOPHARMACY: A SAFE AND EFFECTIVE APPROACH The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GUATEMALA PAKISTAN ALBANIA HAITI PALAU ALGERIA HOLY SEE PANAMA ANGOLA HONDURAS PARAGUAY ARGENTINA HUNGARY PERU ARMENIA ICELAND PHILIPPINES AUSTRALIA INDIA POLAND AUSTRIA INDONESIA PORTUGAL AZERBAIJAN IRAN, ISLAMIC REPUBLIC OF QATAR BANGLADESH IRAQ REPUBLIC OF MOLDOVA BELARUS IRELAND ROMANIA BELGIUM ISRAEL RUSSIAN FEDERATION BELIZE ITALY SAUDI ARABIA BENIN JAMAICA SENEGAL BOLIVIA JAPAN SERBIA BOSNIA AND HERZEGOVINA JORDAN SEYCHELLES BOTSWANA KAZAKHSTAN BRAZIL KENYA SIERRA LEONE BULGARIA KOREA, REPUBLIC OF SINGAPORE BURKINA FASO KUWAIT SLOVAKIA CAMEROON KYRGYZSTAN SLOVENIA CANADA LATVIA SOUTH AFRICA CENTRAL AFRICAN LEBANON SPAIN REPUBLIC LIBERIA SRI LANKA CHAD LIBYAN ARAB JAMAHIRIYA SUDAN CHILE LIECHTENSTEIN SWEDEN CHINA LITHUANIA SWITZERLAND COLOMBIA LUXEMBOURG SYRIAN ARAB REPUBLIC COSTA RICA MADAGASCAR TAJIKISTAN CÔTE D’IVOIRE MALAWI THAILAND CROATIA MALAYSIA THE FORMER YUGOSLAV CUBA MALI REPUBLIC OF MACEDONIA CYPRUS MALTA TUNISIA CZECH REPUBLIC MARSHALL ISLANDS TURKEY DEMOCRATIC REPUBLIC MAURITANIA UGANDA OF THE CONGO MAURITIUS UKRAINE DENMARK MEXICO UNITED ARAB EMIRATES DOMINICAN REPUBLIC MONACO UNITED KINGDOM OF ECUADOR MONGOLIA GREAT BRITAIN AND EGYPT MONTENEGRO NORTHERN IRELAND EL SALVADOR MOROCCO ERITREA MOZAMBIQUE UNITED REPUBLIC ESTONIA MYANMAR OF TANZANIA ETHIOPIA NAMIBIA UNITED STATES OF AMERICA FINLAND NEPAL URUGUAY FRANCE NETHERLANDS UZBEKISTAN GABON NEW ZEALAND VENEZUELA GEORGIA NICARAGUA VIETNAM GERMANY NIGER YEMEN GHANA NIGERIA ZAMBIA GREECE NORWAY ZIMBABWE The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters, New York; it entered into force on 29 July 1957. The Headquarters of the Agency are situated in Vienna.
    [Show full text]
  • Preparation and Dispensing Problems Associated with Technetium Tc-99M Radiopharmaceuticals
    THE UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals VOLUME 11, LESSON 1 Preparation and Dispensing Problems Associated with Technetium Tc-99m Radiopharmaceuticals By James A. Ponto, MS, RPh, BCNP University of Iowa Hospitals and Clinics, and College of Pharmacy Iowa City, IA The University of New Mexico Health Sciences Center College of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. Program No. 039- 000-04-003-H04. Expires May 25, 2007. 2.5 Contact Hours of .25 CEUs. Preparation and Dispensing Problems Associated with Technetium Tc-99m Radiopharmaceuticals By: James A. Ponto Coordinating Editor and Director of Pharmacy Continuing Education William B. Hladik III, MS, RPh College of Pharmacy University of New Mexico Health Sciences Center Managing Editor Julliana Newman, ELS Wellman Publishing, Inc. Albuquerque, New Mexico Editorial Board George H. Hinkle, MS, RPh, BCNP William B. Hladik III, MS, RPh David Laven, NPh, CRPh, FASHP, FAPhA Jeffrey P. Norenberg, MS, PharmD, BCNP, FASHP Neil A. Petry, RPh, MS, BCNP, FAPhA Timothy M. Quinton, PharmD, MS, RPh, BCNP Guest Reviewer Joseph Hung, PhD Director, Nuclear Pharmacy Laboratories and Positron Emission Tomography (PET) Radiochemistry Facility Mayo Clinic 200 First St. S.W. Rochester, MN 55905 While the advice and information in this publication are believed to be true and accurate at press time, the author(s), editors, or the publisher cannot accept any legal responsibility for any errors or omissions that may be made. The publisher makes no war- ranty, express or implied, with respect to the material container herein.
    [Show full text]
  • Azedra) Reference Number: ERX.SPA.420 Effective Date: 03.01.21 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
    Clinical Policy: Iobenguane I-131 (Azedra) Reference Number: ERX.SPA.420 Effective Date: 03.01.21 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Iobenguane I-131 (Azedra®) injection is a radioactive agent. FDA Approved Indication(s) Azedra is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary. It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Azedra is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Pheochromocytoma and Paraganglioma (must meet all): 1. Diagnosis of pheochromocytoma or paraganlioma; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 12 years; 4. Tumor is unresectable, locally advanced, or metastatic; 5. Member currently receives medication to control tumor secretion of catecholamines (e.g., epinephrine, norepinephrine, dopamine) and related symptoms (e.g., hypertension, arrhythmia, hyperglycemia); 6. Metaiodobenzylguanidine (MIBG) scan is positive; 7. Concurrent radiopharmaceuticals have not been prescribed (e.g., Lutathera® [lutetium lu-177 dotatate]); 8. Request meets one of the following (a or b):* a. Dose does not exceed (i or ii): i.
    [Show full text]
  • Submission to the Nuclear Power Debate Personal Details Kept Confidential
    Submission to the Nuclear power debate Personal details kept confidential __________________________________________________________________________________________ Firstly I wish to say I have very little experience in nuclear energy but am well versed in the renewable energy one. What we need is a sound rational debate on the future energy requirements of Australia. The calls for cessation of nuclear investigations even before a debate begins clearly shows that emotion rather than facts are playing a part in trying to stop the debate. Future energy needs must be compliant to a sound strategy of consistent, persistent energy supply. This cannot come from wind or solar. Lets say for example a large blocking high pressure weather system sits over the Victorian, NSW land masses in late summer- autumn season. We will see low winds for anything up to a week, can the energy market from the other states support the energy needs of these states without coal or gas? I think not. France has a large investment in nuclear energy and charges their citizens around half as much for it than Germany. Sceptics complain about the costs of storage of waste, they do not suggest what is going to happen to all the costs to the environment when renewing of derelict solar panels and wind turbine infrastructure which is already reaching its use by dates. Sceptics also talk about the dangers of nuclear energy using Chernobyl, Three Mile Island and Fuklushima as examples. My goodness given that same rationale then we should have banned flight after the first plane accident or cars after the first car accident.
    [Show full text]
  • COMMENT (11) Status: Pending Post PUBLIC SUBMISSION PUBLICATION Tracking No
    Page 1 of 2 SUNSI Review Complete Template = ADM-013 E-RIDS=ADM-03 ADD: Jazel Parks, As of: 10/1/19 1:22 PM Harriet Karagiannis Received: September 25, 2019 COMMENT (11) Status: Pending_Post PUBLIC SUBMISSION PUBLICATION Tracking No. 1k3-9ce3-dnzr DATE: 7/26/2019 Comments Due: September 26, 2019 CITATION 84 FR Submission Type: Web 36127 Docket: NRC-2019-0154 Release of Patients Administered Radioactive Material Comment On: NRC-2019-0154-0003 Release of Patients Administered Radioactive Material; Extension of comment period Document: NRC-2019-0154-DRAFT-0012 Comment on FR Doc # 2019-17060 Submitter Information Name: Daniel Miron Address: W176S8019 Joel Drive Muskego, WI, 53150 Email: [email protected] General Comment I am pleased to comment on the draft regulatory guide (DG), DG-8057, Release of Patients Administered Radioactive Material that was published in the Federal Register on July 26, 2019. (Docket ID NRC-2019- 0154). I am a health physicist who is certified by the American Board of Health Physics and have over 25 years of health physics experience in medical health physics. This includes being the Radiation Safety Officer (RSO) on multiple limited scope and broad scope medical licenses. I recommend that the data for I-123 NaI in table 3 Activities of Radiopharmaceuticals That Require Instructions and Records When Administered to Patients Who Are Breastfeeding an Infant or Child be reviewed and updated to reflect the current clinical use of I-123 NaI. Specifically the recommended duration of interruption of breastfeeding should be changed to Complete cessation due to the reasons listed below.
    [Show full text]
  • Radiation Quick Reference Guide Recommend Contacting Your State Fusion Center
    Domestic Nuclear Detection Office If you encounter something suspicious follow your specific local protocols. Radiation Quick Reference Guide Recommend contacting your state fusion center. DNDO is available 24/7 to assist at 1-877-DNDO-JAC / 1-877-363-6522 JAC Information Line 202-254-7179 Email: [email protected] Nuclear Concerns/ Threats 1. Nuclear Weapon - a device that releases nuclear energy in an ex- Isotopes of Concern for use in RDDs - with common uses plosive manner. Uses Highly Enriched Uranium (HEU) and/or 1. Cobalt-60 – cancer treatment, level/ Plutonium. density gauge, teletherapy, radiography, 2. Improvised Nuclear Device (IND) - a nuclear weapon fabricated food sterilization/irradiation, by a terrorist organization or rogue nation. brachytherapy 2. Iridium-192 – Radiography/non- destructive testing, flaw detection, brachy- therapy “cancer seed”, skin cancer Cobalt 60 sources Uranium “superficial” brachytherapy Plutonium 3. Uranium a. Uranium exists naturally in the earth’s crust. Of the different “isotopes” of uranium, U-235 is the one required to produce a Iridium sentinel and nuclear weapon. gamma camera b. Natural uranium contains a small amount of U-235 (<1%) which Cesium Seeds must be separated in complex extraction processes to create HEU. The predominant uranium isotope is U-238. 3. Cesium-137 - Gauge/level gauge, industrial radiography, brachyther- c. Highly Enriched Uranium (HEU) refers to uranium usable in weap- apy/teletherapy, well logging/density gauges ons due to its enrichment in U-235. 4. Strontium-90 – Radioisotope thermoelectric generator (RTG), fis- d. Approximately 25 kg of HEU is required for a nuclear weapon. sion product, industrial gauges, medical treatment e.
    [Show full text]
  • A New Gamma Camera for Positron Emission Tomography
    INIS-mf—11552 A new gamma camera for Positron Emission Tomography NL89C0813 P. SCHOTANUS A new gamma camera for Positron Emission Tomography A new gamma camera for Positron Emission Tomography PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR AAN DE TECHNISCHE UNIVERSITEIT DELFT, OP GEZAG VAN DE RECTOR MAGNIFICUS, PROF.DRS. P.A. SCHENCK, IN HET OPENBAAR TE VERDEDIGEN TEN OVERSTAAN VAN EEN COMMISSIE, AANGEWEZEN DOOR HET COLLEGE VAN DECANEN, OP DINSDAG 20 SEPTEMBER 1988TE 16.00 UUR. DOOR PAUL SCHOTANUS '$ DOCTORANDUS IN DE NATUURKUNDE GEBOREN TE EINDHOVEN Dit proefschrift is goedgekeurd door de promotor Prof.dr. A.H. Wapstra s ••I Sommige boeken schijnen geschreven te zijn.niet opdat men er iets uit zou leren, maar opdat men weten zal, dat de schrijver iets geweten heeft. Goethe Contents page 1 Introduction 1 2 Nuclear diagnostics as a tool in medical science; principles and applications 2.1 The position of nuclear diagnostics in medical science 2 2.2 The detection of radiation in nuclear diagnostics: 5 standard techniques 2.3 Positron emission tomography 7 2.4 Positron emitting isotopes 9 2.5 Examples of radiodiagnostic studies with PET 11 2.6 Comparison of PET with other diagnostic techniques 12 3 Detectors for positron emission tomography 3.1 The absorption d 5H keV annihilation radiation in solids 15 3.2 Scintillators for the detection of annihilation radiation 21 3.3 The detection of scintillation light 23 3.4 Alternative ways to detect annihilation radiation 28 3-5 Determination of the point of annihilation: detector geometry,
    [Show full text]
  • Gamma Cameras
    OECD Health Statistics 2021 Definitions, Sources and Methods Gamma cameras Number of Gamma cameras. A Gamma camera (including Single Photon Emission Computed Tomography, SPECT) is used for a nuclear medicine procedure in which the camera rotates around the patient to register gamma rays emission from an isotope injected to the patient's body. The gathered data are processed by a computer to form a tomographic (cross-sectional) image. Inclusion - SPECT-CT systems using image fusion (superposition of SPECT and CT images). Sources and Methods Australia Source of data: Department of Health. Unpublished data from Location Specific Position Number register. Reference period: Years reported are financial years 1st July to 31st June (e.g. data for 2012 are as at 30th June 2012). Coverage: Data from 2008 onwards represent the number of units approved for billing to Medicare only. Units may be removed from one location and re-registered in another location. Austria Source of data: Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection / Gesundheit Österreich GmbH, Monitoring of medical technology development. Reference period: 31st December. Coverage: - Included are all Gamma cameras units in hospitals as defined by the Austrian Hospital Act (KAKuG) and classified as HP.1 according to the System of Health Accounts (OECD). - The ambulatory sector is included (HP.3). Belgium Source of data: Federal Service of Public Health, DGGS “Organisation of health provisions”; Ministry of the Flemish community and Ministry of the French community. Coverage: - Ambulatory care providers (HP.3): Data on high-tech equipment in cabinets of ambulatory care providers are not available.
    [Show full text]
  • HISTORY Nuclear Medicine Begins with a Boa Constrictor
    HISTORY Nuclear Medicine Begins with a Boa Constrictor Marshal! Brucer J Nucl Med 19: 581-598, 1978 In the beginning, a boa constrictor defecated in and then analyzed the insoluble precipitate. Just as London and the subsequent development of nuclear he suspected, it was almost pure (90.16%) uric medicine was inevitable. It took a little time, but the acid. As a thorough scientist he also determined the 139-yr chain of cause and effect that followed was "proportional number" of 37.5 for urea. ("Propor­ inexorable (7). tional" or "equivalent" weight was the current termi­ One June week in 1815 an exotic animal exhibi­ nology for what we now call "atomic weight.") This tion was held on the Strand in London. A young 37.5 would be used by Friedrich Woehler in his "animal chemist" named William Prout (we would famous 1828 paper on the synthesis of urea. Thus now call him a clinical pathologist) attended this Prout, already the father of clinical pathology, be­ scientific event of the year. While he was viewing a came the grandfather of organic chemistry. boa constrictor recently captured in South America, [Prout was also the first man to use iodine (2 yr the animal defecated and Prout was amazed by what after its discovery in 1814) in the treatment of thy­ he saw. The physiological incident was common­ roid goiter. He considered his greatest success the place, but he was the only person alive who could discovery of muriatic acid, inorganic HC1, in human recognize the material. Just a year earlier he had gastric juice.
    [Show full text]
  • The Supply of Medical Isotopes
    The Supply of Medical Isotopes AN ECONOMIC DIAGNOSIS AND POSSIBLE SOLUTIONS The Supply of Medical Isotopes AN ECONOMIC DIAGNOSIS AND POSSIBLE SOLUTIONS The Supply of Medical Isotopes AN ECONOMIC DIAGNOSIS AND POSSIBLE SOLUTIONS This work is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of OECD member countries. This document, as well as any data and any map included herein, are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. Please cite this publication as: OECD/NEA (2019), The Supply of Medical Isotopes: An Economic Diagnosis and Possible Solutions, OECD Publishing, Paris, https://doi.org/10.1787/9b326195-en. ISBN 978-92-64-94550-0 (print) ISBN 978-92-64-62509-9 (pdf) The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli authorities. The use of such data by the OECD is without prejudice to the status of the Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of international law. Photo credits: Cover © Yok_onepiece/Shutterstock.com. Corrigenda to OECD publications may be found on line at: www.oecd.org/about/publishing/corrigenda.htm. © OECD 2019 You can copy, download or print OECD content for your own use, and you can include excerpts from OECD publications, databases and multimedia products in your own documents, presentations, blogs, websites and teaching materials, provided that suitable acknowledgement of OECD as source and copyright owner is given.
    [Show full text]